Obesity-Related Glomerulopathy: Clinical Management

Michal Herman-Edelstein*, Talia Weinstein, Avry Chagnac

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Obesity-related glomerulopathy (ORG) and other obesity-associated kidney diseases pose a major challenge to the treating nephrologist. We review the benefits of weight loss and optimal management of ORG and kidney disease in the setting of obesity. Therapeutic strategies in ORG were limited mainly in the past to weight loss through lifestyle interventions and bariatric surgery, antihypertensive treatment, and renin-angiotensin-aldosterone system blockade. Current approaches to obtain the desired weight loss include novel pharmacologic therapies that have been approved for the treatment of diabetes while offering kidney protection, such as sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1–receptor agonists. This review focuses on the nephroprotective role of the renin-angiotensin-aldosterone system blockade and of these new pharmacologic agents, and on the renal effects of bariatric surgery in chronic kidney disease.

Original languageEnglish
Pages (from-to)358-370
Number of pages13
JournalSeminars in Nephrology
Issue number4
StatePublished - Jul 2021


  • Obesity-related glomerulopathy
  • obesity-associated kidney diseases


Dive into the research topics of 'Obesity-Related Glomerulopathy: Clinical Management'. Together they form a unique fingerprint.

Cite this